Publication
Hypomethylating agents with venetoclax for newly diagnosed acute myeloid leukemia in patients 65 and older in The Netherlands - A nationwide study of drug usage and treatment outcomes.
Benno Diekmann, Carolien M Woolthuis, Maarten F Corsten, David de Leeuw, Roel B Fiets, Elena Segarceanu, Fleur M van der Valk, Tim T de Waal, Marjan Cruijsen, Eva de Jongh, Tjeerd Snijders, Danielle van Lammeren, Aart Beeker, Alexandra H E Herbers, Lidwine Tick, Bas Franken, Nic J G M Veeger, Eric N van Roon, Mels Hoogendoorn
- Source
- PubMed
- Retrieved
- Sep 19, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260919-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
INTRODUCTION: For patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy the combination of a hypomethylating agent (HMA) with venetoclax (VEN) has become the standard of care. DESIGN: We conducted a retrospective real-world study across 15 hospitals involving…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerLeukemiadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available